会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NOVEL REGIMENS OF TAFENOQUINE FOR PREVENTION OF MALARIA IN MALARIA-NAÏVE SUBJECTS
    • 疟疾预防疟疾的泰铢新规
    • WO2016089995A1
    • 2016-06-09
    • PCT/US2015/063425
    • 2015-12-02
    • 60 DEGREES PHARMACEUTICALS, LLCSMITH, Bryan L.JONES, John PaulSCHMUKLARSKY, MosheBUDDA, Balasubrahmanyan
    • SMITH, Bryan L.JONES, John PaulSCHMUKLARSKY, MosheBUDDA, BalasubrahmanyanDOW, Geoffrey S.
    • C07D215/40A61K31/47
    • A61K31/4706A61P33/06C07D215/40Y02A50/411
    • Methods of prevention of symptomatic malaria in a malaria-naïve, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I). A compound of Formula (I) can be administered prior to potential exposure of a species of Plasmodium , during potential exposure of a species of Plasmodium , and after potential exposure of a species of Plasmodium . The methods of the invention also pertains to kits comprising specific doses of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I), and instructions for administration of dosing quantity and frequency. The methods of the invention also pertain to determining doses of Formula (I) that meet the general regulatory requirement for a drug to be efficacious in the prevention of malaria in malaria-naïve subjects. The methods of the invention further pertain to using the described algorithm to derive dosing regimens which can provide protection against symptomatic malaria in malaria-naïve, G6PD-normal subjects.
    • 包括向人受试者施用式(I)化合物,其药学上可接受的盐或包含式(I)化合物的药物组合物的方法,在疟疾初始的G6PD-正常人受试者中预防有症状的疟疾的方法。 一种式(I)化合物可以在潜在暴露一种疟原虫之前,潜在暴露于一种疟原虫之前,以及一种疟原虫种类潜在的暴露之后进行。 本发明的方法还涉及包含特定剂量的式(I),其药学上可接受的盐或包含式(I)化合物的药物组合物和给药剂量和频率的说明书的试剂盒。 本发明的方法还涉及确定符合药物在疟疾初始受试者中有效预防疟疾的一般调节要求的式(I)的剂量。 本发明的方法进一步涉及使用所描述的算法来推导给药方案,其可以在无疟疾,G6PD-正常受试者中提供针对症状性疟疾的保护。